Indian multinational pharmaceutical company, Zydus Lifesciences Limited, has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Niacin Extended-Release ...

Zydus Lifesciences Limited has earned USFDA approval for Niacin Extended-Release Tablets used to treat high cholesterol.

Zydus MedTech has partnered with Brazil-based Braile Biomedica to commercialize innovative TAVI technology across Europe, India, and other markets. The collaboration seeks to address the rising demand ...

Zydus Lifesciences Limited announces the execution of undertakings from 7 shareholders to tender 2,236,911 Amplitude Surgical ...

Ahmedabad: Zydus Lifesciences Limited has announced the execution of undertakings from 7 shareholders to tender 2,236,911 Amplitude Surgical shares, representing 4.7% of the company’s capital and ...

AHMEDABAD, India and PARIS, April 17, 2025 /PRNewswire/ -- Following the announcement of its envisaged tender offer on March 11, 2025, Zydus Lifesciences Limited announces the execution of ...

Jay Kothari , Director of Zynext Ventures, highlighted, "Feldan's platform has the potential to transform intracellular delivery and pioneer next-generation therapeutics, aligning with the disruptive ...

PENNINGTON, N.J. and QUÉBEC, April 16, 2025 /CNW/ -- Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Feldan ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Financial terms were not disclosed. Zynext Ventures is the investment arm of Ahmedabad, Gujarat, India based Zydus Lifesciences Limited (NSE: ZYDUSLIFE; BSE: 532321), a global life sciences company.